VIA
NXTM

Vident Investment Advisory’s NxStage Medical Inc. NXTM Stock Holding History

Vident Investment Advisory’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-20,435
Closed -$511K – 402
2016
Q3 		$511K Buy
+20,435
New +$476K 0.07% 341

Other funds holding NXTM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Vident Investment Advisory's NXTM Position: Q4 2016 in Review

Vident Investment Advisory sold out of NxStage Medical Inc. (NXTM) in Q4 2016, closing a stake of 20,435 shares — an estimated $511K sold.

Vident Investment Advisory first reported a position in NXTM in Q3 2016 and held it in 1 quarter. The position peaked at $511K in Q3 2016. 170 funds tracked by Wall St. Rank hold NXTM as of Q4 2016.

  • Vident Investment Advisory reported no remaining NxStage Medical Inc. position as of Q4 2016 after selling out during the quarter.
  • Vident Investment Advisory sold 20,435 NxStage Medical Inc. shares in Q4 2016, an estimated $511K.
  • Vident Investment Advisory first reported a position in NxStage Medical Inc. in Q3 2016 and held it in 1 quarter.
  • Vident Investment Advisory's NxStage Medical Inc. position peaked at $511K in Q3 2016.
  • 170 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q4 2016.

Based on Vident Investment Advisory's 13F filing for Q4 2016, filed 14 Feb 2017.